1887

Abstract

Interleukin-10 (IL-10) plays a critical role in Epstein–Barr virus (EBV) biology. Indeed, the EBV genome contains a gene (BCRF1) with homology to the human IL-10 (hIL-10) gene. In addition to viral IL-10, which is secreted late in the productive cycle, hIL-10 production is also induced in B cells infected by EBV. The EBV protein LMP-1 and the viral small non-polyadenylated RNAs (EBERs) expressed during latency are involved in hIL-10 induction. In this study, we show that in B cells the viral transcription factor EB1, which is the main inducer of the EBV productive cycle, also activates transcription of the hIL-10 gene and secretion of the hIL-10 protein. Accordingly, EB1 bound directly to specific DNA sequences in the hIL-10 minimal promoter. Moreover, specific disruption of EB1 binding to some of these sites impaired EB1-mediated activation of transcription at the hIL-10 promoter in a transient expression assay. Therefore, an increase in IL-10 production occurs during latency and early and late during the productive cycle. This production of IL-10 might favour the survival of EBV-infected cells and/or create a microenvironment required for efficient infection of B lymphocytes by EBV virions.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18845-0
2003-04-01
2020-05-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/4/vir840965.html?itemId=/content/journal/jgv/10.1099/vir.0.18845-0&mimeType=html&fmt=ahah

References

  1. Adamson A. L., Kenney S.. 2001; Epstein–Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol75:2388–2399
    [Google Scholar]
  2. Badou A., Bennasser Y., Moreau M., Leclerc C., Benkirane M., Bahraoui E.. 2000; Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol74:10551–10562
    [Google Scholar]
  3. Bejarano M. T., Masucci M. G.. 1998; Interleukin-10 abrogates the inhibition of Epstein–Barr virus-induced B-cell transformation by memory T-cell responses. Blood92:4256–4262
    [Google Scholar]
  4. Birkeland S. A., Bendtzen K., Moller B., Hamilton-Dutoit S., Andersen H. K.. 1999; Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation67:876–881
    [Google Scholar]
  5. Cayrol C., Flemington E. K.. 1995; Identification of cellular target genes of the Epstein–Barr virus transactivator Zta: activation of transforming growth factor β igh3 (TGF- β igh3) and TGF- β 1. J Virol69:4206–4212
    [Google Scholar]
  6. Chevallier-Greco A., Manet E., Chavrier P., Mosnier C., Daillie J., Sergeant A.. 1986; Both Epstein–Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J5:3243–3249
    [Google Scholar]
  7. Cortes J., Kurzrock R.. 1997; Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma26:251–259
    [Google Scholar]
  8. Countryman J., Jenson H., Seibl R., Wolf H., Miller G.. 1987; Polymorphic proteins encoded within BZLF1 of defective and standard Epstein–Barr viruses disrupt latency. J Virol61:3672–3679
    [Google Scholar]
  9. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M. G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J. E.. 1991; Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med174:915–924
    [Google Scholar]
  10. de Waal Malefyt R., Yssel H., de Vries J. E.. 1993; Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol150:4754–4765
    [Google Scholar]
  11. Erickson K. D., Martin J. M.. 2000; The late lytic LMP-1 protein of Epstein–Barr virus can negatively regulate LMP-1 signaling. J Virol74:1057–1060
    [Google Scholar]
  12. Eskdale J., Kube D., Tesch H., Gallagher G.. 1997; Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics46:120–128
    [Google Scholar]
  13. Farrell P. J., Rowe D. T., Rooney C. M., Kouzarides T.. 1989; Epstein–Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c- fos . EMBO J8:127–132
    [Google Scholar]
  14. Flemington E., Speck S. H.. 1990; Epstein–Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c- fos . J Virol64:4549–4552
    [Google Scholar]
  15. Giot J. F., Mikaelian I., Buisson M., Manet E., Joab I., Nicolas J. C., Sergeant A.. 1991; Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required. Nucleic Acids Res19:1251–1258
    [Google Scholar]
  16. Herbst H., Foss H. D., Samol J., Araujo I., Klotzbach H., Krause H., Agathanggelou A., Niedobitek G., Stein H.. 1996; Frequent expression of interleukin-10 by Epstein–Barr virus-harboring tumor cells of Hodgkin's disease. Blood87:2918–2929
    [Google Scholar]
  17. Hudson G. S., Farrell P. J., Barrell B. G.. 1985; Two related but differentially expressed potential membrane proteins encoded by the Eco RI Dhet region of Epstein–Barr virus B95-8. J Virol53:528–535
    [Google Scholar]
  18. Keating S., Prince S., Jones M., Rowe M.. 2002; The lytic cycle of Epstein–Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol76:8179–8188
    [Google Scholar]
  19. Kieff E., Rickinson A. B.. 2001; Epstein–Barr virus and its replication. In Fields Virology , 4th edn. pp 2511–2573 Edited by Knipe D. M., Howley P. M.. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
  20. Kitagawa N., Goto M., Kurozumi K., Maruo S., Fukayama M., Naoe T., Yasukawa M., Hino K., Suzuki T., Todo S., Takada K.. 2000; Epstein–Barr virus-encoded poly(A) (−)RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J19:6742–6750
    [Google Scholar]
  21. Klein S. C., Kube D., Abts H., Diehl V., Tesch H.. 1996; Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection. Leuk Res20:633–636
    [Google Scholar]
  22. Kube D., Platzer C., von Knethen A., Straub H., Bohlen H., Hafner M., Tesch H.. 1995; Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine7:1–7
    [Google Scholar]
  23. Lieberman P. M., Hardwick J. M., Sample J., Hayward G. S., Hayward S. D.. 1990; The zta transactivator involved in induction of lytic cycle gene expression in Epstein–Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol64:1143–1155
    [Google Scholar]
  24. Lu J., Chen S. Y., Chua H. H., Liu Y. S., Huang Y. T., Chang Y., Chen J. Y., Sheen T. S., Tsai C. H.. 2000; Upregulation of tyrosine kinase TKT by the Epstein–Barr virus transactivator Zta. J Virol74:7391–7399
    [Google Scholar]
  25. Manet E., Gruffat H., Trescol-Biemont M. C., Moreno N., Chambard P., Giot J. F., Sergeant A.. 1989; Epstein–Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J8:1819–1826
    [Google Scholar]
  26. Mikaelian I., Drouet E., Marechal V., Denoyel G., Nicolas J. C., Sergeant A.. 1993; The DNA-binding domain of two bZIP transcription factors, the Epstein–Barr virus switch gene product EB1 and Jun, is a bipartite nuclear targeting sequence. J Virol67:734–742
    [Google Scholar]
  27. Miyazaki I., Cheung R. K., Dosch H. M.. 1993; Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein–Barr virus. J Exp Med178:439–447
    [Google Scholar]
  28. Moore K. W., Vieira P., Fiorentino D. F., Trounstine M. L., Khan T. A., Mosmann T. R.. 1990; Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein–Barr virus gene BCRFI. Science248:1230–1234
    [Google Scholar]
  29. Moore K. W., de Waal Malefyt R., Coffman R. L., O'Garra A.. 2001; Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol19:683–765
    [Google Scholar]
  30. Morrison T. E., Mauser A., Wong A., Ting J. P., Kenney S. C.. 2001; Inhibition of IFN- γ signaling by an Epstein–Barr virus immediate-early protein. Immunity15:787–799
    [Google Scholar]
  31. Nakagomi H., Dolcetti R., Bejarano M. T., Pisa P., Kiessling R., Masucci M. G.. 1994; The Epstein–Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer57:240–244
    [Google Scholar]
  32. Ohshima K., Suzumiya J., Akamatu M., Takeshita M., Kikuchi M.. 1995; Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes. Int J Cancer62:5–10
    [Google Scholar]
  33. Payvandi F., Amrute S., Fitzgerald-Bocarsly P.. 1998; Exogenous and endogenous IL-10 regulate IFN- α production by peripheral blood mononuclear cells in response to viral stimulation. J Immunol160:5861–5868
    [Google Scholar]
  34. Rickinson A. B., Kieff E.. 1996; Epstein-Barr virus. In Fields Virology , 3rd edn. pp 2397–446 Edited by Fields B. N., Knipe D. M., Howley P. M.. Philadelphia: Lippincott–Raven;
    [Google Scholar]
  35. Rickinson A. B., Moss D. J.. 1997; Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. Annu Rev Immunol15:405–431
    [Google Scholar]
  36. Rousset F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu D. H., Kastelein R., Moore K. W., Banchereau J.. 1992; Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A89:1890–1893
    [Google Scholar]
  37. Sairenji T., Ohnishi E., Inouye S., Kurata T.. 1998; Induction of interleukin-10 on activation of Epstein–Barr virus in EBV-infected B-cell lines. Viral Immunol11:221–231
    [Google Scholar]
  38. Schepers A., Pich D., Hammerschmidt W.. 1993; A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein–Barr virus. EMBO J12:3921–3929
    [Google Scholar]
  39. Shaw P. E., Bohmann D., Sergeant A.. 1985; The SV40 enhancer influences viral late transcription in vitro and in vivo but not on replicating templates. EMBO J4:3247–3252
    [Google Scholar]
  40. Speck S. H., Chatila T., Flemington E.. 1997; Reactivation of Epstein–Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol5:399–405
    [Google Scholar]
  41. Swaminathan S., Hesselton R., Sullivan J., Kieff E.. 1993; Epstein–Barr virus recombinants with specifically mutated BCRF1 genes. J Virol67:7406–7413
    [Google Scholar]
  42. Thorley-Lawson D. A.. 2001; Epstein–Barr virus: exploiting the immune system. Nature Rev Immunol1:75–82
    [Google Scholar]
  43. Urier G., Buisson M., Chambard P., Sergeant A.. 1989; The Epstein–Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J8:1447–1453
    [Google Scholar]
  44. Vockerodt M., Haier B., Buttgereit P., Tesch H., Kube D.. 2001; The Epstein–Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology280:183–198
    [Google Scholar]
  45. Yao M., Ohshima K., Suzumiya J., Kume T., Shiroshita T., Kikuchi M.. 1997; Interleukin-10 expression and cytotoxic-T-cell response in Epstein–Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer72:398–402
    [Google Scholar]
  46. Yoshizaki T., Sato H., Murono S., Pagano J. S., Furukawa M.. 1999; Matrix metalloproteinase 9 is induced by the Epstein–Barr virus BZLF1 transactivator. Clin Exp Metastasis17:431–436
    [Google Scholar]
  47. Zeidler R., Eissner G., Meissner P., Uebel S., Tampe R., Lazis S., Hammerschmidt W.. 1997; Downregulation of TAP1 in B lymphocytes by cellular and Epstein–Barr virus-encoded interleukin-10. Blood90:2390–2397
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18845-0
Loading
/content/journal/jgv/10.1099/vir.0.18845-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error